Accelerating the biopharma lifecycle management with Industry 4.0

Find out why more than 60 per cent of biopharma organizations still manage their critical process steps with paper and Microsoft Office

Add bookmark

Pharma IQ
03/23/2021

red-and-blue-test-tubes-in-the-lab

We respect your privacy, by clicking "Download Your Copy" you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. You have the right to object. In addition, you will receive our e-newsletter, including information on related online learning opportunities. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here.

The Covid-19 pandemic placed a renewed focus on accelerating the digitalization efforts of life sciences and reducing the time of bringing a new drug to market. Biopharma companies that embrace the benefits of Industry 4.0 will unlock the potential to emerge as industry leaders.

This white paper created by IDBS, explores the bold vision that is Biopharma 4.0 and how to start the journey toward an advanced digital lab. In this report, IDBS provides best practices for scaling quickly using data from equipment, instruments and sensors to accelerate the biopharma lifecycle management, and provide the fuel needed to dive speed and innovation in the lab.

Download this white paper to find out why:

  • Biopharmaceuticals can transform global health.
  • Development time lost is the cost of the problem.
  • More than 60 per cent of biopharma organizations are still managing their critical process steps with paper, impacting operational effectiveness in biopharma development.
  • First-to-market advantages are only seen in fewer than half of cases after 10 years.
  • Extending intellectual property of a product will secure companies a place as a market leader.

We respect your privacy, by clicking "Download Your Copy" you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. You have the right to object. In addition, you will receive our e-newsletter, including information on related online learning opportunities. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here.

RECOMMENDED